Sana Biotechnology(US:SANA) Prnewswire·2025-05-06 09:45Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Sana Biotechnology, Inc. misrepresented its financial stability and the potential of its product candidates, specifically SC291 in oncology, SC379, and SG299 [2]. - Allegations include that Sana was at significant risk of insufficient funds to maintain operations and advance product candidates, and that the company was likely to decrease funding for certain projects and reduce its workforce [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until May 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].